Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2176643 | 0.98 | NPC1 (0.61) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL12487147 | 0.96 | NPC1 (0.64) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| Dioxane SCHEMBL28234086 | 0.90 | NPC1 (0.54) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL414719 | 0.86 | MEN1 (0.70) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL2174012 | 0.85 | SCN9A (0.61) | NPC1MEN1KMT2ARAB9AEGFR | |
| SCHEMBL2283204 | 0.85 | NPC1 (0.68) | NPC1MEN1KMT2AEGFRERBB3 | |
| SCHEMBL3952295 | 0.84 | EGFR (0.66) | NPC1MEN1KMT2ACYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL2176150 | 0.83 | NPC1 (0.66) | NPC1MEN1KMT2AEGFRERBB3 | |
| SCHEMBL690494 | 0.83 | EGFR (0.56) | NPC1MEN1KMT2ARAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2173883 | 0.82 | EGFR (0.64) | NPC1MEN1KMT2ACYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519501-B1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS | UNIV WIEN TECH (AT) | 2015-04-22 | — | — | EP | disclosed |
| US-8986994-B2 | Substituted pyridines and pyrimidines | TECHNISCHE UNIVERSITAET WIEN (AT) | 2015-03-24 | — | — | US | disclosed |
| US-8986994-B2 | Substituted pyridines and pyrimidines | TECHNISCHE UNIVERSITAET WIEN (AT) | 2015-03-24 | — | — | US | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | MEDIZINISCHE UNIVERSITAET WIEN (AT) | 2012-11-22 | — | — | US | disclosed |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | MEDIZINISCHE UNIVERSITAET WIEN (AT) | 2012-11-22 | — | — | US | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
| CN-1276920-C | Thiazolidinedione derivatives and pharmaceutical compositions containing the same | CHONG KUN DANG PHARM CORP (KR) | 2006-09-27 | — | — | CN | disclosed |
| EP-1490360-A4 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2006-07-05 | — | — | EP | disclosed |
| CN-1622945-A | Thiazolidinedione derivatives and pharmaceutical composition comprising the same | CHONG KUN DANG PHARM CORP (KR) | 2005-06-01 | — | — | CN | disclosed |
| EP-1490360-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2004-12-29 | — | — | EP | disclosed |
| US-6787551-B2 | ORAL ADMINISTRATION; TREATING INSULIN RESISTANCE USING A NEW MECHANISM TO LOWER BLOOD SUGAR LEVEL BY INCREASING PHYSIOLOG-ICAL EFFECTS OF INSULIN ON TARGET CELLS (MUSCLE, ADIPOCYTES, LIVER); ALSO STRONGER ANTILIPIDEMIC THAN ROSIGLITAZONE | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2004-09-07 | — | — | US | disclosed |
| US-20040122031-A1 | Thiazolidinedione and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2004-06-24 | — | — | US | disclosed |
| WO-2003080605-A1 | THIAZOLIDINEDIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | NPC1 2863/4885MEN1 1165/4885KMT2A 811/4885 |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | NPC1 2566/4885MEN1 3696/4885KMT2A 2628/4885 |
| US-20120294835-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES | TNNI3, TNNT2, PROX1 | NPC1 4262/4885MEN1 4740/4885KMT2A 2502/4885 |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | NPC1 1273/4885MEN1 2920/4885KMT2A 2282/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | NPC1 1132/4885MEN1 3264/4885KMT2A 3064/4885 |
| US-20040122031-A1 | Thiazolidinedione and pharmaceutical composition comprising the same | GLP1R, PPARD, SLC5A1 | NPC1 370/4885MEN1 3913/4885KMT2A 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.